ABOUT US

Where science meets strategy in preclinical hematology

MIMO Biosciences emerged from twelve years of pioneering research at CIMA Universidad de Navarra. We are specialists in translating scientific insight into high-impact preclinical solutions for the pharmaceutical and biotechnology industry. Our mission is clear: to accelerate the delivery of innovative therapies to patients with hematological cancers

We stand out through our in-house, precision-driven approach. Every mouse model we develop results from rigorous internal processes and is highly customized to meet our clients’ specific needs. We don’t offer generic solutions; we create tailored preclinical tools designed for your unique projects, from early-stage discovery to final validation.

Precision & Customization

Your Ally in Every Preclinical Phase

We understand the complexities of drug development. That’s why we act as your comprehensive ally, capable of supporting any part of your preclinical process. Whether you need to validate an initial biomarker or conduct large-scale efficacy trials, our experts and models seamlessly integrate into your strategy, significantly streamlining your pre-clinical efforts

Your Ally in Every Preclinical Phase

Our models are built and validated in-house, underpinned by a robust track record of peer-reviewed publications, including work in Nature Medicine (2023). This ensures the reliability and relevance of our data for real-world drug development. Our 15 research agreements with major pharmaceutical companies in the last 3 years stand as a testament to the trust placed in our expertise

Scientifically Validated & Trusted

Collaboration Phases

Your Preclinical Process with MIMO

At MIMO Biosciences, we integrate into every stage of your preclinical research, offering flexible, expert support. Our process covers:

1

Drug Development & Safety

Precise Design & Evaluation. We support drug development from medicinal chemistry to critical toxicology and pharmacology studies. This includes molecular design and thorough in vivo safety and biodynamic assessment using our models.

2

Model Implementation & Disease Tracking

Dynamic Disease Monitoring. We conduct in vivo imaging (Micropet), histopathology, and multiparametric flow cytometry. This phase enables real-time disease progression tracking and detailed tissue/cell characterization.

3

Molecular Profiling

Cutting-Edge Genomic Analysis. We utilize Next Generation Sequencing (NGS) and other genetic / transcriptomic analyses. We identify key biomarkers and mechanisms of action in both our murine models and human samples.

4

Data Integration & Analysis

Data Intelligence for Strategic Decisions. We integrate multi-omic and phenotypic data using advanced biostatistics, bioinformatics, and our Artificial Intelligence platform. We transform complex data into actionable insights for your therapy development

Syngeneic

GEMMs

GEMMs

PDX

Humanised Xenograft

ABOUT US

Where science meets strategy in preclinical hematology